In the realm of modern medicine, few advancements have had such a transformative impact on pediatric critical care as Extracorporeal Membrane Oxygenation (ECMO). ECMO is an advanced life support therapy providing temporary cardiopulmonary support by oxygenating the blood, removing carbon dioxide and maintaining systemic perfusion. The origins of ECMO can be traced back to the 1950s when researchers began exploring the possibilities of utilizing extracorporeal circulation, adapted from cardiopulmonary bypass to support failing organ systems. However, it wasn’t until the 1970s that the potential of ECMO in pediatric patients was truly recognized, sparking a new era of innovation. Initially reserved for only the most dire cases, such as newborns with meconium aspiration syndrome, ECMO indications have expanded to include cardiac failure, circulatory failure, and eCPR. Advances in technology, including the introduction of centrifugal pumps, biocompatible circuits, and oxygenators with enhanced gas exchange capabilities, further improved the safety and efficacy of ECMO support. Simultaneously, the establishment of specialized ECMO centers and the formation of international collaborations fostered the exchange of knowledge and standardized practices, facilitating the widespread adoption of ECMO as a viable treatment option for critically ill children worldwide. Beyond technological advancements, there has also been a significant impact of clinical research on the evolution of pediatric ECMO. Researchers have sought to elucidate the optimal indications, timing, and duration of ECMO therapy. Additionally, long-term follow-up studies have shed light on the neurodevelopmental outcomes of ECMO survivors, providing valuable insights into the potential benefits and challenges associated with this life-saving intervention.